Volibris 5mg

The drug Volibris is indicated for pulmonary arterial hypertension of the second and third functional class. The main active substance of the drug is the antagonist of endothelin receptors Ambrisentan. The product is available in film-coated tablets of 5 mg.

Getting into the body, Ambrisentan blocks the receptors of endothelin – a substance that plays a key role in the development of the pathology of pulmonary arterial hypertension. The agent acts selectively and significantly increases the cardiac index. It is rapidly absorbed into the digestive tract and reaches a maximum in the blood 1.5 hours after ingestion.

Ambrisentan is excreted through the intestines, as well as with bile flow. The sex and age of patients do not affect the pharmacokinetics of the drug. In terms of removing the remedy from the body, liver and kidney diseases also have no clinical significance, and it is not recommended to prescribe the drug to patients with severe liver function tests. The schedule of food intake does not affect the action of Volibris.

The course of treatment is carried out under strict medical supervision. The initial dose for adults should not exceed 5 mg per day for a single dose. With good tolerability, the dose of Volibris is increased to 10 mg per day once. With simultaneous treatment with cyclosporine, the maximum daily dose should not exceed 5 mg. The use of the drug in patients under 18 years is not recommended.
In case of an overdose with Volibris, there may be dizziness, headache, nasal congestion, nausea, lowering of blood pressure. In these cases, the doctor prescribes and controls the symptomatic treatment.

During the research, it has been found that taking the drug increases the risk of congenital malformations, so before the start of therapy special tests are conducted to confirm the absence of pregnancy. The course of treatment for patients of reproductive age is accompanied by the selection of the optimal method of contraception. Pregnancy should be excluded also within 3 months after the end of therapy. Breastfeeding during treatment with Volibris is stopped. In addition to the above information, a contraindication to taking the drug is lactose intolerance.